Ulcerative colitis treatment follows a step-up approach: milder disease starts with anti-inflammatory medications taken by mouth or applied rectally, while moderate-to-severe disease requires stronger drugs that calm the immune system. The goal isn’t just to feel better. Doctors now aim for mucosal healing, meaning the lining of your colon looks normal or near-normal on a scope, because that reduces the risk of flares, hospitalization, and surgery over time.
Anti-Inflammatory Medications for Mild Disease
If your ulcerative colitis is mild to moderate, the first treatment is almost always a type of drug called a 5-ASA (mesalamine). These medications work directly on the inflamed lining of the colon to reduce swelling. The standard oral dose is 2.4 grams per day, typically split into three doses, taken for at least six weeks to get a flare under control. Many people stay on mesalamine long-term to prevent flares from returning.
Where your inflammation sits in the colon matters. If it’s limited to the rectum or the lower end of the colon, rectal formulations (enemas or suppositories) deliver the drug right to the problem area and often work faster than pills alone. For proctitis, a nightly suppository for three to six weeks is a common starting point. For disease that extends a bit higher, a retention enema used at bedtime works well. Combining an oral 5-ASA with a rectal one is more effective than using either by itself, and this combination is one of the most important strategies for mild-to-moderate UC that isn’t responding to pills alone.
Steroids for Active Flares
When a flare hits hard enough that 5-ASA medications can’t keep up, corticosteroids are the standard rescue therapy. The typical starting dose for a moderate-to-severe flare is 40 mg of prednisone per day. It usually takes five to seven days before you and your doctor can tell whether steroids are working.
If they are, you’ll stay at that dose for two to four weeks, then begin a gradual taper. A common approach is to reduce by 5 mg per week until you reach 20 mg, then slow down to 2.5 mg per week until you’re off entirely. Rushing the taper is one of the most common reasons flares bounce back. For severe UC that requires hospitalization, intravenous steroids are used instead.
Steroids are effective at putting out fires, but they don’t maintain remission and carry significant side effects with long-term use, including bone loss, weight gain, and mood changes. If you’ve needed two or more courses of steroids in a year, or you can’t taper off without symptoms returning, that’s a clear signal to move to a stronger maintenance therapy.
Biologics for Moderate-to-Severe UC
Biologic therapies are lab-made proteins that target specific parts of the immune system driving inflammation. They’ve transformed outcomes for people with moderate-to-severe ulcerative colitis. Several classes are now available, each working through a different mechanism.
TNF blockers were the first biologics approved for UC. Infliximab, adalimumab, and golimumab all work by neutralizing a protein called TNF-alpha, which is found in high concentrations in the inflamed colon tissue of UC patients. Infliximab is given by infusion at a clinic, while adalimumab and golimumab are self-injected at home. These drugs bind to TNF-alpha both in the bloodstream and on the surface of immune cells, preventing it from triggering further inflammation.
Vedolizumab takes a different approach. Instead of blocking an inflammatory protein, it prevents certain immune cells from migrating into the gut in the first place. Because it acts specifically on gut-directed immune cells, it tends to have fewer body-wide side effects than TNF blockers. Newer biologics that target the inflammatory pathways driven by IL-23, another immune signaling protein, are also approved for UC and offer yet another option when other treatments haven’t worked.
Before starting any biologic, you’ll need screening tests. Tuberculosis testing (usually a blood test plus a chest X-ray) and hepatitis B blood work are required, because these drugs suppress parts of the immune system that keep latent infections in check. If either test comes back positive, treatment for the infection typically needs to start before beginning the biologic.
Newer Oral Options: Small Molecule Drugs
Unlike biologics, which are large proteins given by injection or infusion, small molecule drugs are pills. Two main classes are now approved for moderate-to-severe UC.
JAK inhibitors block enzymes inside immune cells that relay inflammatory signals. Tofacitinib, upadacitinib, and filgotinib are all approved for UC. They tend to work relatively quickly, and because they’re oral, many patients prefer them over injections. Your doctor will monitor blood counts and cholesterol levels while you’re on these medications.
S1P receptor modulators, including ozanimod and etrasimod, work by trapping certain immune cells in lymph nodes so fewer of them reach the colon. They can cause a temporary slowing of the heart rate when first started, so the first dose is sometimes monitored, and an eye exam may be recommended to check for a rare side effect involving the retina.
Surgery When Medications Aren’t Enough
About 15 to 20 percent of people with ulcerative colitis will eventually need surgery. Unlike Crohn’s disease, UC is limited to the colon, so removing the colon and rectum is curative. The most common procedure creates an internal pouch from the end of the small intestine and connects it to the anal canal, allowing you to have bowel movements without a permanent external bag.
Long-term data on this surgery are encouraging. In a study following patients for over a decade, pouch success rates were 92.3% at five years, 88.7% at ten years, and 84.5% at fifteen years. The most common complication is pouchitis, an inflammation of the new pouch, which is usually treatable with antibiotics. Quality of life tends to be good, though people over 50 and those who develop frequent pouchitis or higher stool frequency report somewhat lower satisfaction.
Surgery isn’t a last resort or a failure. For people dealing with frequent hospitalizations, steroid dependence, or a colon that simply doesn’t respond to available medications, it can be the most effective path to feeling normal again.
The Role of Diet
Diet alone doesn’t replace medication for ulcerative colitis, but it can meaningfully affect symptoms and possibly inflammation. The specific carbohydrate diet (SCD), which eliminates most grains, processed sugars, and certain starches, has the most clinical data behind it for UC. In a 12-week trial, UC patients following the SCD saw their disease activity scores drop from an average of 28.3 to 6.7, along with lower markers of inflammation in their blood. A separate study found that people with IBD in remission who followed the SCD reported reduced symptoms and some were able to stop medications entirely.
These are small studies, and results vary from person to person. But the consistent finding is that restricting certain carbohydrates appears to shift gut bacteria in a favorable direction. If you’re interested in trying a dietary approach alongside your medications, working with a dietitian who understands IBD can help you avoid nutritional gaps while identifying which foods worsen your symptoms.
What Treatment Success Looks Like
The definition of successful treatment has shifted significantly. Feeling better, while important, isn’t enough on its own. The current target is mucosal healing, defined as a Mayo endoscopic score of 0 or 1, meaning a colonoscopy shows little to no visible inflammation. Patients who achieve mucosal healing have lower rates of flares, fewer hospitalizations, and a reduced need for surgery compared to those who feel well but still have inflammation visible on a scope.
This is why your gastroenterologist will recommend follow-up colonoscopies even when you feel fine. Ongoing low-grade inflammation that you can’t feel still damages the colon over time and increases colorectal cancer risk. Treatment adjustments based on what the scope shows, not just how you feel, lead to better long-term outcomes.